A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancer

Crizotinib has achieved astonishing success in advanced non‐small‐cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangement. However, no real‐world studies described the clinicopathological characteristics and treatment of such patients in China. Patients were consec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gang, Chen, Xi, Zhang, Yaxiong, Yan, Fang, Fang, Wenfeng, Yang, Yunpeng, Hong, Shaodong, Miao, Siyu, Wu, Manli, Huang, Xiaodan, Luo, Youli, Zhou, Cong, Gong, Run, Huang, Yan, Zhou, Ningning, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430086/
https://www.ncbi.nlm.nih.gov/pubmed/28374971
http://dx.doi.org/10.1002/cam4.1059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430086/
https://www.ncbi.nlm.nih.gov/pubmed/28374971
http://dx.doi.org/10.1002/cam4.1059

Ejemplares similares